VELDHOVEN, the Netherlands - ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program.
| Date | Total repurchased shares | Weighted average price | Total repurchased value |
| 19-Feb-18 | - | - | - |
| 20-Feb-18 | - | - | - |
| 21-Feb-18 | - | - | - |
| 22-Feb-18 | 5,000 | 157.33 | 786,625.00 |
| 23-Feb-18 | - | - | - |
ASML's current share buyback program was announced on 17 January 2018, and details are available on our website at https://www.asml.com/investors/share-buyback/en/s25436
This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).
| Media Relations Contacts | Investor Relations Contacts |
| Monique Mols, phone +31 6 528 444 18 | Skip Miller, phone +1 480 235 0934 |
| Niclas Mika, phone +31 6 201 528 63 | Marcel Kemp, phone +31 40 268 6494 |


Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Shein Scales Back Vietnam Operations as US Trade Rules Shift
OpenAI Restricts Astra AI Over Cyberattack Risks
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 



